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Invasive fungal disease is a significant cause
of morbidity and mortality in the neonate. The
current study aims to assess the 1, 3-bD-Glucan
(BG)  assay  in  a  prospective  analysis  in
neonates with suspected fungaemia. A multi-
centre, prospective cohort study was conducted
in  Johannesburg,  South  Africa.  The  study
included 72 neonates with clinically suspected
late onset sepsis who were at high risk of fun-
gaemia.  A  BG  assay  was  performed  on  each
patient and correlated with a sepsis classifica-
tion based on the full blood count, C-reactive
protein  and  blood  culture  results  as  no  fun-
gaemia,  possible  fungaemia,  probable  fun-
gaemia or definite fungaemia. Sensitivity and
specificity of the BG assay at levels of 60 pg/mL
are 73.2% and 71.0% respectively and at levels of
80  pg/mL  are  70.7%  and  77.4%  respectively.
Positive  and  negative  predictive  values  at  60
pg/mL are 76.9% and 66.7% respectively and at
80 pg/mL are 80.6% and 66.7% respectively. The
area  under  the  receiver  operating  curve  is
0.753. The BG assay is a useful adjunct to the
diagnosis  of  invasive  fungal  disease  in
neonates. It does, however, need to be consid-
ered in the context of the clinical picture and
supplementary laboratory investigations.
Introduction
Neonatal mortality contributes approximately
36% to under-5 deaths globally.1 In South Africa,
the neonatal mortality rate is 21/1000 live births
with 21% of these deaths being due to severe
infections.2 The  impact  of  neonatal  sepsis  is
clearly a significant one. Fungaemia is becom-
ing increasingly important as a cause and is
associated with substantial morbidity and mor-
tality in the preterm infant.3,4
Candida species rapidly colonize the skin and
mucous  membranes  of  critically  ill  neonates
which can progress to invasive infection. This is
particularly so in critically ill neonates who are
at  increased  risk  of  fungal  infection  due  to
immature immune systems, increased perme-
ability  of  skin  and  mucous  membranes,  par-
enteral  nutrition,  broad-spectrum  antibiotics,
central venous catheters, postnatal steroids and
mechanical ventilation.4 This high-risk popula-
tion could benefit greatly from early diagnosis.
The diagnosis of sepsis in neonates, including
invasive fungal disease, is difficult as the clini-
cal presentation is often subtle and signs are
often nonspecific.5There is no single diagnostic
test available to reliably confirm or refute sepsis
on presentation. Currently diagnosis is based
on a combination of clinical features and labo-
ratory  investigations  such  as  the  full  blood
count (FBC), C reactive protein (CRP), erythro-
cyte  sedimentation  rate  (ESR)  and  procalci-
tonin (PCT), amongst others.5,6 Definitive diag-
nosis  depends  on  a  positive  blood  culture  in
keeping with clinical features and other labora-
tory  investigations.  Blood  cultures  are  often
negative in neonates even in the presence of
sepsis.7This is even more problematic with fun-
gal infections as blood cultures are only positive
in approximately 50% of cases of invasive can-
didiasis  and  less  than  10%  of  invasive
aspergillosis.8,9
1, 3-b-D-Glucan (BG) is a component of the
outer  wall  of  a  number  of  fungi  including
Candida species,  Aspergillus species  and
Pneumocystis jiroveci. The antigen is released
into the bloodstream during invasive infection
due to such fungi and can be detected by the
Fungitell™ assay.10 This assay uses enzymes
from  the  Limulus  polyphemus amoebocyte
lysate and removes bacterial endotoxin-sensi-
tive factor C from the lysate to form a reagent.
BG from patient serum binds to Factor G in the
reagent and activates the horseshoe crab coag-
ulation  cascade  allowing  quantitative  assay.
Values >80 pg/mL are considered positive, 60-
80  pg/mL  are  considered  equivocal  (repeat
testing recommended) and values less than 60
pg/mL are considered negative.10 The sensitiv-
ity and specificity of the BG assay for invasive
fungal  infections  is  reported  as  69.9%  and
87.1% respectively.10 Studies to date are based
on  adult  haematological,  immunocompro-
mised,  cancer  and  surgical  patients.  Little
information  is  available  with  regard  to
neonates. New diagnostic markers are needed
to improve the early diagnosis of fungaemia in
newborns.  The  current  study  comprised  a
prospective analysis to determine the useful-
ness of the BG assay for detection of fungal
antigen in clinically suspected neonatal inva-
sive  fungal  disease  at  three  academic
Hospitals in Johannesburg.  
Objectives
To determine the 1, 3-b-D-Glucan assay in a
prospective  diagnostic  analysis  in  neonates
with suspected fungaemia. To correlate possi-
ble, probable or definite fungaemia with BG
assay results and determine the sensitivity and
specificity of the test in neonates.
Materials and Methods
Study design
A  multicentre,  prospective  cohort  study  was
conducted including 72 neonates admitted to the
neonatal units at Charlotte Maxeke Johannesburg
Academic  Hospital  (CMJAH),  Rahima  Moosa
Mother  and  Child  Hospital  and  Chris  Hani
Baragwanath Hospital in Johannesburg.
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Patient selection 
Patients with clinically suspected late onset
sepsis,  defined  as  onset  of  sepsis  after  72
hours of life, were identified and classified as
no  or  high  risk  for  invasive  fungal  disease.
Patients were regarded as high risk for inva-
sive fungal disease and were eligible for inclu-
sion in the study if they had 3 or more of the
following criteria: i) Low birth weight (<2500
g); ii) Duration of hospitalisation > 3 weeks;
iii) Prolonged invasive (intermittent positive
pressure) ventilation or non-invasive (contin-
uous positive pressure) ventilation (>1 week);
iv)  Systemic  antibiotic  exposure  >72  hours,
including poor clinical response to first or sec-
ond  line  antibiotic  therapy;  v)  Postoperative
patients  or  patients  with  abdominal  wall
defects; vi) Central venous or arterial catheter-
isation >72 hours; vii) Received total parenter-
al  nutrition  (TPN);  viii)  Splenomegaly;  ix)
Persistent  severe  thrombocytopenia  (platelet
count  <100,000/mm3 despite  second  line
antibiotic treatment).
Patients on systemic antifungal therapy prior
to  investigation  for  new  onset  sepsis  were
excluded. Patients fulfilling the above criteria
were investigated for sepsis as per unit proto-
col.  This  included  blood  investigations  (FBC
with platelet count, CRP and blood culture) as
well  as  urine  cultures,  lumbar  puncture  and
radiological investigations where indicated.  
Laboratory investigations 
The blood investigations included an FBC
with platelet count, CRP and blood culture col-
lected in a FAN blood culture bottle (as per lab-
oratory  standard  operative  procedures).  In
addition to these investigations, a sample of
blood was drawn for a 1, 3-b-D-Glucan assay.
The  assay  was  performed  using  the
Fungitell™ assay kit (Fungitell® Cape Cod)
and  was  performed  in  the  Microbiology
Laboratory at CMJAH according to manufac-
turer instructions. The assay was performed
in duplicate on each sample and the average
of the results obtained was determined. In the
case  of  extremely  discrepant  results,  the
results  have  been  described  as  uninter-
pretable. Further investigations such as lum-
bar puncture and radiological investigations
were  performed  at  the  discretion  of  the
attending  physician.  Informed  consent  was
obtained  from  the  primary  caregiver  before
inclusion  in  the  study.  This  study  was
approved  by  the  Human  Research  Ethics
Committee  of  the  University  of  the
Witwatersrand (approval number M090211).
Diagnostic criteria for invasive 
fungal disease 
Based on the above investigations patients
were categorised as one of the following: i) no
fungaemia: a high index of suspicion for fun-
gaemia  including  3  or  more  risk  factors  as
described above; blood culture negative; white
cell  count  (WCC),  platelet  count  (<100
000/mm3) and C-reactive protein (CRP) with-
in normal limits; no evidence of colonisation
with a fungal organism; OR definite bacterial
sepsis; ii) possible fungaemia: a high index of
suspicion for fungaemia including 3 or more
risk factors as described above; blood cultures
negative; no evidence of colonisation; two or
more of the following present: abnormal WCC,
low platelet count or elevated CRP (>10); iii)
probable fungaemia: a high index of suspicion
for fungaemia including 3 or more risk factors
as described above PLUS evidence of colonisa-
tion with a fungal organism in the form of pos-
itive stool or non-sterile urine sample (collect-
ed  by  urine  bag)  for  yeasts;  blood  cultures
negative; and one or more of the following are
present:  abnormal  WCC,  low  platelet  count 
(<100 000/mm3) or elevated CRP (>10); iv)
definite fungaemia: positive culture for a fun-
gal  organism  from  a  normally  sterile  site
(including  blood  or  tissue  culture).  The  BG
results were correlated with the classification
as  described  above,  no  fungaemia,  possible
fungaemia,  probable  fungaemia  or  definite
fungaemia. 
Statistical analysis
The  sample  comprised  72  neonates.
Continuous variables (including birth weight
and gestational age) were not normally dis-
tributed and have therefore been described as
median and range. Categorical variables have
been described using proportions. Sensitivity
and  specificity  of  the  1,3-b-D-Glucan  assay
have been determined and the positive and
negative  predictive  values  of  the  test  have
been calculated. The categories possible, prob-
able and definite fungaemia were combined
and considered diagnostic for fungaemia for
the purpose of statistical analysis. The catego-
ry no infection or confirmed bacterial infec-
tion were analysed as no fungaemia. Receiver
operating  curves  have  been  used  to  further
analyse the results.
Results
The initial sample included 79 neonates of
which 72 formed part of the analysis. Of the
seven potential candidates removed from the
study,  two  caregivers  refused  consent,  two
samples were rejected at laboratory level (one
was contaminated and the other was haemol-
ysed), two samples had a laboratory error and
one  result  was  uninterpretable.  The  sample
characterisitics are summarized in Table 1. 
Correlation  of  sepsis  category  with  blood
culture results, evidence of colonisation and
1,3-bD-Glucan  assay  level  are  presented  in
Table 2. Fungal culture from a normally sterile
site was positive in 10 cases (nine blood sam-
ples and one tissue sample). Four of the sam-
ples cultured Candida albicans, four cultured
Candida  parapsilosis,  one  cultured
Sacchyromyces cerevisiae and one blood cul-
ture was reported as yeast but not identified.
The lowest BG assay in cases with a positive
fungal culture was 109 pg/mL with seven fun-
gal culture positive cases having a BG assay
>500  pg/mL.  In  the  categories  possible  fun-
Article




Birth weight (g)      1340 (720-4600)1
Gestational age (weeks) 31 (26-40)1





Central venous / arterial catheter 30 (41.7%)
Previous antibiotic exposure 72 (100%)
Empiric antifungal therapy 18 (25%)
1Median and range; 2Surgical diagnoses included NEC III, gastroschi-
sis,  omphalocoele,  intestinal  atresia/stenosis,  intestinal  perfora-
tion, imperforate anus, tracheosophageal fistula, colonic duplication
cyst, congenital diaphragmatic hernia; 3Intermittent positive pres-
sure ventilation;  4Continuous positive airway pressure;  5High fre-
quency oscillatory ventilation; 6Total parenteral nutrition.
Table 2. Correlation of sepsis category with blood culture results and 1,3-bD-Glucan
assay level (n=72).
Sepsis n Positive Positive Evidence of 1,3-ßD-Glucan assay level
category1 fungal bacterial colonisation3 <60 61-80 >80
culture2 culture2
1 31 0 13 7 22 27
2 22 00 2 71 14
39 0 2 94 0 5
4 10 10 13 0 0 10
1Sepsis categories as described under methods;  2Positive cuture from a normally sterile site (including blood or tissue culture); 3Stool or non-
sterile urine sample (urine bag specimen) positive for yeasts.[Pediatric Reports 2011; 3:e14] [page 47]
gaemia and probable fungaemia, in which cul-
tures  from  a  normally  sterile  site  remained
negative  and  invasive  fungal  disease  would
previously  not  have  been  diagnosed,  there
were  an  additional  19  BG  assay  levels 
>80 pg/mL. 
The  sensitivity  and  specificity  of  the  BG
assay at levels of 60 pg/mL are 73.2% and 71.0%
respectively and at levels of 80 pg/mL are 70.7%
and 77.4% respectively. The positive and nega-
tive predictive values at 60 pg/mL are 76.9%
and  66.7%  respectively  and  at  80  pg/mL  are
80.6% and 66.7% respectively. In addition, the
area under the ROC curve is 0.753. Sensitivity,
specificity and positive and negative predictive
values  calculated  according  to  varying  BG
assay levels are presented in Table 3. ROC sta-
tistics and curve are presented in Figure 1.
Discussion
The current study shows the 1,3-bD-Glucan
assay to be a useful adjunct in the diagnosis of
fungaemia in neonates. Existing recommenda-
tions for positivity and negativity of the assay
appear to be appropriate for the neonatal peri-
od. Despite reasonable sensitivity and speci-
ficity of the 1,3-bD-Glucan assay, there remain
a significant number of false positive and false
negative results. 
Potential causes of false positive reactivity
include patients or specimens exposed to BG
containing  products  (for  example  gauzes),
patients undergoing haemodialysis with cellu-
lose containing membranes, patients receiving
intravenous  immunoglobulin  therapy  and
exposure  to  the  antibiotic  amoxicillin-clavu-
lanic acid.11 Albumin, clotting factors and plas-
ma  protein  concentrates  are  manufactured
using filters containing high concentrations of
BG and may lead to false positivity. In addition,
the bacterial organisms Streptococcus pneumo-
niae and Alcaligenes faecalis are known to con-
tain b-1,3-glucan in their cell walls and may
also  cause  false  reactivity.11 Other  bacteria,
specifically  gram  positive  organisms  and
Pseudomonas aeruginosa, may also cause false
positive reactivity.12,13
The early diagnosis and treatment of fun-
gaemia,  which  has  been  shown  to  decrease
mortality, is challenging.14The blood culture as
the  gold  standard of  diagnosis  is  limited  by
delays of 18 to 72 hours to achieve positivity.8
In addition, only 50% of invasive candidiasis
and less than 10% of invasive aspergillosis are
blood culture positive. This curtails the poten-
tial survival benefit of earlier antifungal treat-
ment.  A  reasonable  clinical  approach  to  the
neonate with suspected fungaemia is to com-
mence antifungal therapy based on a positive
1,3-bD-Glucan  assay  result  (which  can  be
obtained within 24 hours) whilst blood culture
results are pending. In the case of a positive
1,3-bD-Glucan  assay  result  and  a  negative
blood culture result one needs to consider both
the  degree  of  positivity  (for  example1,3-bD-
Glucan assay levels > 250 pg/mL have a speci-
ficity  of  96.8%)  and  the  presence  of  factors
causing false positive reactivity. Results also
need to be interpreted taking the infant’s clin-
ical presentation into consideration.
One of the difficulties in the current study
was  the  criteria  used  for  diagnosing  fun-
gaemia. Use of the blood culture as gold stan-
dard would be ideal but the yield of positive
blood cultures in neonatal sepsis is known to
be low.7 This led to the use of alternative crite-
ria  for  the  diagnosis  of  fungaemia  which,
although unavoidable, may lead to inaccura-
cies in the analysis. A similar dilemma sur-
rounding diagnostic criteria is demonstrated
in a previous study by Odabasi et al.15 In this
study  sensitivity  and  specificity  of  the  BG
assay at a level of 60 pg/mL are reported as
100% and 90% respectively for proven or prob-
able fungaemia and 70% and 96% respectively
for proven, probable or possible fungaemia.  
Limitations of the BG assay include the cost
of the test (particularly important in a develop-
ing country such as South Africa) and the lack
of species identification. A positive BG assay
result indicates the presence of one of a num-
ber of possible fungi, including amongst others
Candida species, the most common fungal iso-
late  in  neonates.3 It  is,  however,  dependent
upon the blood culture for identification and
sensitivity of the causative organism. For this
reason the BG assay may be of particular use
in an epidemic or nosocomial outbreak setting.  
Conclusions
The BG assay is a useful adjunct to the diag-
nosis of fungaemia in neonates with a predic-
tive value of 0.753 on ROC analysis. BG varies
in specificity, depending on the cut-off values
used, due to a number of false positive results.
The assay therefore needs to be considered in
the context of the clinical picture and supple-
mentary  laboratory  investigations.  Ongoing
research  is  required  into  further  causes  of
false  positive  reactivity  and  the  change  in
assay levels in response to treatment.
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